• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison.

作者信息

Bomanji J, Levison D A, Flatman W D, Horne T, Bouloux P M, Ross G, Britton K E, Besser G M

出版信息

J Nucl Med. 1987 Jun;28(6):973-8.

PMID:3585505
Abstract

The percentage uptake of [123I]metaiodobenzylguanidine (MIBG) by tumors of the paraganglion system is compared with the number of neurosecretory granules (assessed by both light and electron microscopy) in the subsequently resected tumors in six patients. Iodine-123 MIBG was injected intravenously; the tumor uptake of [123I]MIBG varied between 0.001% and 0.14% of the injected dose per gram of tumor tissue at 22 hr. The number of neurosecretory granules in tissue sections was scored on a scale of I-III. A direct proportional correlation was found between the percentage uptake of [123I]MIBG by the tumor and the number of neurosecretory granules in the tissue sections but not with plasma or urinary catecholamines. This technique for imaging reflects the storage status of the tumor better than plasma and urinary catecholamine measurements.

摘要

相似文献

1
Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison.
J Nucl Med. 1987 Jun;28(6):973-8.
2
[Scintigraphy with iodine-131 metaiodobenzylguanidine in the study of paraganglioma. Comparison between benign and malignant tumors].[碘 - 131间碘苄胍闪烁扫描术在副神经节瘤研究中的应用。良性与恶性肿瘤的比较]
Radiol Med. 1994 May;87(5):688-93.
3
Pre- and post-treatment distribution pattern of 123I-MIBG in patients with phaeochromocytomas and paragangliomas.
Nucl Med Commun. 1989 Aug;10(8):567-76. doi: 10.1097/00006231-198908010-00005.
4
Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.放射性标记的奥曲肽与间碘苄胍(MIBG)闪烁扫描术在恶性嗜铬细胞瘤中的比较。
J Nucl Med. 1995 Jan;36(1):1-6.
5
Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma.除嗜铬细胞瘤和神经母细胞瘤外的神经内分泌肿瘤的碘-131间碘苄胍闪烁显像。
J Nucl Med. 1987 Jun;28(6):979-88.
6
Meta-[I-131]iodobenzylguanidine uptake in a nonsecreting paraganglioma.
J Nucl Med. 1984 Sep;25(9):984-6.
7
Imaging neural crest tumours with 123I-metaiodobenzylguanidine and X-ray computed tomography: a comparative study.用123I-间碘苄胍和X射线计算机断层扫描对神经嵴肿瘤进行成像:一项比较研究。
Clin Radiol. 1988 Sep;39(5):502-6. doi: 10.1016/s0009-9260(88)80214-9.
8
Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.嗜铬细胞瘤和副神经节瘤的检测与治疗:间碘苄胍闪烁显像的现状及正电子发射断层显像的未来作用
Q J Nucl Med Mol Imaging. 2008 Dec;52(4):419-29.
9
Iodine-123-4-amino-3-iodobenzylguanidine, a new sympathoadrenal imaging agent: comparison with iodine-123 metaiodobenzylguanidine.
J Nucl Med. 1986 Jul;27(7):1138-42.
10
Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.生长抑素受体闪烁扫描术(锝[HYNIC,Tyr3]-奥曲肽)和123I-间碘苄胍闪烁扫描术在计算机断层扫描检测出的与SDHx基因相关的嗜铬细胞瘤和副神经节瘤患者中的应用价值
Neuroendocrinology. 2015;101(4):321-30. doi: 10.1159/000381458. Epub 2015 Mar 13.

引用本文的文献

1
Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review.碘-123间碘苄胍(I-123 MIBG)的临床应用:综述
Pharmaceuticals (Basel). 2024 Nov 21;17(12):1563. doi: 10.3390/ph17121563.
2
Usefulness of the Primary Tumor Standardized Uptake Value of Iodine-123 Metaiodobenzylguanidine for Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma.碘-123间碘苄胍原发性肿瘤标准化摄取值对预测嗜铬细胞瘤和副神经节瘤转移潜能的价值
Mol Imaging Biol. 2024 Dec;26(6):1005-1015. doi: 10.1007/s11307-024-01952-8. Epub 2024 Sep 18.
3
A Case of Pheochromocytoma With Coagulation Necrosis Due to Hypertensive Crisis Aggravated by Contrast-Enhanced CT Scan and Negative 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy.
1例因对比增强CT扫描加重高血压危象并伴有凝血坏死的嗜铬细胞瘤及123I-间碘苄胍(MIBG)闪烁扫描阴性病例
Cureus. 2024 Mar 25;16(3):e56878. doi: 10.7759/cureus.56878. eCollection 2024 Mar.
4
A Case of I-Metaiodobenzylguanidine Scintigraphy-Negative Pheochromocytoma with a Tumor-Developing Mutation in the Gene.一例基因存在肿瘤发展突变的间碘苄胍闪烁显像阴性嗜铬细胞瘤病例
J Clin Med. 2022 Aug 8;11(15):4624. doi: 10.3390/jcm11154624.
5
Dosing Therapeutic Radiopharmaceuticals in Obese Patients.肥胖患者的治疗性放射性药物给药。
Int J Mol Sci. 2022 Jan 13;23(2):818. doi: 10.3390/ijms23020818.
6
Ga-DOTATATE PET/CT Compared with I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors.镓- DOTATATE PET/CT与碘- MIBG SPECT/CT在神经嵴肿瘤评估中的比较
Asia Ocean J Nucl Med Biol. 2020 Winter;8(1):8-17. doi: 10.22038/aojnmb.2019.41343.1280.
7
Utility of I-MIBG Standardized Uptake Value in Patients with Refractory Pheochromocytoma and Paraganglioma.I-MIBG标准化摄取值在难治性嗜铬细胞瘤和副神经节瘤患者中的应用价值
Asia Ocean J Nucl Med Biol. 2019 Spring;7(2):115-120. doi: 10.22038/AOJNMB.2019.35953.1245.
8
Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine.转移性嗜铬细胞瘤和副神经节瘤患者的靶向放射性核素治疗:从低比活度到高比活度碘-131间碘苄胍
Cancers (Basel). 2019 Jul 20;11(7):1018. doi: 10.3390/cancers11071018.
9
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.欧洲核医学协会实践指南/核医学与分子影像学会2019年嗜铬细胞瘤和副神经节瘤放射性核素成像程序标准
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137. doi: 10.1007/s00259-019-04398-1. Epub 2019 Jun 29.
10
A phase I clinical trial for [I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma.一项关于[I]meta-碘苄胍治疗耐药性嗜铬细胞瘤和副神经节瘤患者的 I 期临床试验。
Sci Rep. 2019 May 20;9(1):7625. doi: 10.1038/s41598-019-43880-6.